Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 05 February 2018 | By Michael Mezher
The US Food and Drug Administration's (FDA) drugs and biologics centers on Monday released their shared strategy for selecting, developing and implementing data standards over the next five years.
Specifically, the strategy outlines the governance framework and goals for using data standards for the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).
"Together the two centers will leverage their combined resources, talent and expertise to maximize stakeholder collaboration, policy development, and project implementation to develop and use data standards for the effective and efficient review of pre- and postmarket submissions of safety and efficacy data," FDA writes.
FDA also says the data standards strategy is in line with its other major strategic initiatives, such as its Strategic Policy Roadmap and Information Technology Strategic Plan, as well as the 21st Century Cures Act and the its commitments under the recently reauthorized Prescription Drug User Fee Act (PDUFA VI).
According to FDA, the data standards strategy will operate based on three main principles, including favoring consensus-based standards over "government-unique standards" where possible; reducing the regulatory burden by aligning data standards with existing initiatives, laws and regulation; and using or adapting existing data standards when feasible.
FDA also lays out six goals it hopes to achieve through its data standards strategy:
By using common data standards, FDA says it hopes to be able to make the information it gathers from drugmakers more useful.
"Standardized data elements and relationships, for example, that are important to a disease or therapeutic area are essential so that data from multiple trials can be more easily grouped for analysis and reporting, as well as for meta-analyses within and across medical product classes," FDA writes.
Regulatory Focus newsletters
All the biggest regulatory news and happenings.